Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) have been given a consensus rating of “Moderate Buy” by the twenty-seven brokerages that are covering the firm, MarketBeat reports. Five analysts have rated the stock with a hold rating and twenty-two have assigned a buy rating to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $477.1271.

A number of brokerages have commented on ALNY. Needham & Company LLC increased their price target on shares of Alnylam Pharmaceuticals from $520.00 to $529.00 and gave the company a “buy” rating in a research report on Monday, January 12th. Raymond James Financial reaffirmed an “outperform” rating and set a $472.00 target price on shares of Alnylam Pharmaceuticals in a report on Monday, January 12th. Bank of America decreased their target price on shares of Alnylam Pharmaceuticals from $529.00 to $462.00 and set a “buy” rating on the stock in a research report on Friday, January 30th. Oppenheimer started coverage on shares of Alnylam Pharmaceuticals in a research report on Wednesday, January 7th. They set an “outperform” rating and a $500.00 price target for the company. Finally, Jefferies Financial Group decreased their price objective on Alnylam Pharmaceuticals from $550.00 to $549.00 and set a “buy” rating on the stock in a report on Thursday, October 30th.

Insiders Place Their Bets

In other news, EVP Kevin Joseph Fitzgerald sold 2,290 shares of the stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $370.33, for a total transaction of $848,055.70. Following the completion of the sale, the executive vice president directly owned 21,264 shares in the company, valued at approximately $7,874,697.12. This represents a 9.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Tolga Tanguler sold 1,510 shares of the stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $362.87, for a total value of $547,933.70. Following the completion of the sale, the executive vice president owned 29,728 shares of the company’s stock, valued at approximately $10,787,399.36. This trade represents a 4.83% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 56,955 shares of company stock worth $24,072,733. 1.20% of the stock is currently owned by insiders.

Institutional Trading of Alnylam Pharmaceuticals

A number of hedge funds have recently modified their holdings of ALNY. Thematics Asset Management purchased a new stake in Alnylam Pharmaceuticals during the 2nd quarter worth approximately $1,995,000. Mediolanum International Funds Ltd acquired a new position in shares of Alnylam Pharmaceuticals in the third quarter worth $11,389,000. Teacher Retirement System of Texas increased its position in shares of Alnylam Pharmaceuticals by 3.2% during the second quarter. Teacher Retirement System of Texas now owns 36,408 shares of the biopharmaceutical company’s stock worth $11,872,000 after acquiring an additional 1,123 shares during the period. Rakuten Investment Management Inc. acquired a new stake in shares of Alnylam Pharmaceuticals in the third quarter valued at $14,205,000. Finally, Generali Asset Management SPA SGR boosted its holdings in Alnylam Pharmaceuticals by 6,368.0% in the third quarter. Generali Asset Management SPA SGR now owns 3,234 shares of the biopharmaceutical company’s stock valued at $1,475,000 after purchasing an additional 3,184 shares during the period. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

Alnylam Pharmaceuticals stock opened at $328.16 on Monday. Alnylam Pharmaceuticals has a fifty-two week low of $205.87 and a fifty-two week high of $495.55. The company has a debt-to-equity ratio of 4.45, a quick ratio of 2.49 and a current ratio of 2.54. The stock has a market cap of $43.35 billion, a P/E ratio of 1,367.33 and a beta of 0.35. The firm’s fifty day moving average price is $389.54 and its 200-day moving average price is $425.73.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.